Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on Topiramate vs Metformin for Metabolic Syndrome in Schizophrenia
NCT05663749Phase 4Completed
- Sponsor
- AIIMS New Delhi
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of topiramate in metabolic syndrome (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Cardiovascular Risk Score at 8 weeks. Started Sep 2022; status: completed.
02
Drugs
topiramate
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT05663749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663749.